Close Menu

NEW YORK (360Dx) – Biocept said in a regulatory filing that it anticipates net proceed of $5.4 million for an offering of its securities, down from $9.1 million that the firm estimated last week.

In an amended prospectus filed with the US Securities and Exchange Commission today, the company said that it now plans to offer about 5.3 million shares of its common stock as well as warrants to purchase 5.3 million shares of its stock at an assumed combined public offering price of $1.14 per share and related warrant.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.